Mounjaro UK Price Guide: £179-£299/Month + How to Access

The cost of Mounjaro at Boots is a key consideration for anyone exploring private weight management treatment in the UK. Mounjaro (tirzepatide) is a prescription-only injectable medicine licensed for obesity and overweight with weight-related health conditions. Available through Boots Online Doctor and participating pharmacies, it is currently accessed almost exclusively via private prescription for weight management. This article outlines indicative pricing at Boots, how NHS and private costs compare, how to access the service, and what alternative options exist for those weighing up the financial commitment of long-term treatment.

Mounjaro Pricing at Boots Pharmacy

Mounjaro at Boots costs approximately £176 to £334 per month depending on dose, following a gradual escalation from 2.5 mg up to a maximum of 15 mg weekly. Always confirm current pricing directly with Boots, as costs may change.

Mounjaro (tirzepatide) is a prescription-only medicine licensed in the UK for weight management in adults with obesity or overweight with weight-related health conditions.^[1][2] At Boots Pharmacy, Mounjaro is available through their private weight management service.

As of 2024, the indicative cost of Mounjaro at Boots has been reported to range from approximately £176 to £334 per month, depending on the prescribed dose. These figures are indicative only and may have changed; always check directly with Boots Online Doctor or your local Boots pharmacy for current pricing, as costs vary depending on the dose, plan, and any ongoing promotions. The treatment follows a dose-escalation schedule consistent with the UK Summary of Product Characteristics (SmPC): starting at 2.5 mg weekly for four weeks, then increasing in 2.5 mg increments (to 5 mg, 7.5 mg, 10 mg, 12.5 mg) up to a maximum maintenance dose of 15 mg, based on individual response and tolerability. Starter doses are generally at the lower end of the price range, with higher maintenance doses typically costing more.

Boots' service may incorporate an initial clinical consultation with a prescriber, ongoing monitoring, and access to lifestyle support resources, though the exact inclusions vary by plan. Patients should confirm what is covered before committing. Budget for a minimum of several months, as tirzepatide requires gradual dose titration and sustained use to achieve meaningful weight loss outcomes.

Prices may vary due to supply considerations, dose strength, and whether patients are new to the service or continuing treatment. Supply of GLP-1 receptor agonists, including tirzepatide, has been subject to periodic constraints; the Department of Health and Social Care (DHSC) and NHS England have issued supply alerts on this class of medicine. Check with your provider for current availability.

Mounjaro is subject to additional monitoring in the UK (indicated by the black triangle symbol ▼), which allows quick identification of new safety information.^[5]

NHS vs Private Prescription Costs

Most Mounjaro prescriptions for weight management are currently issued privately, costing approximately £176 to £334 per month at Boots. NHS access depends on local ICB commissioning and specialist pathway availability, with NICE TA1026 recommending tirzepatide but not guaranteeing automatic access.

The availability and cost of Mounjaro differ significantly between NHS and private routes. Understanding these differences is essential for patients considering this treatment.

NHS Availability: NICE published Technology Appraisal TA1026 recommending tirzepatide (Mounjaro) for weight management in adults who meet the licensed criteria. However, NHS access is not automatic following a NICE TA. It depends on national commissioning arrangements, local Integrated Care Board (ICB) implementation decisions, availability of specialist weight-management pathways (typically Tier 3 services), and current medicine supply. Patients should contact their GP or local ICB to understand what is available in their area. Separately, tirzepatide is NICE-recommended and available on the NHS for treating type 2 diabetes (NICE TA928), but this is a distinct indication from weight management.

If prescribed through the NHS, patients would pay the standard prescription charge (currently £9.90 per item in England, with exemptions for certain groups; prescriptions are free in Scotland, Wales, and Northern Ireland).

Private Prescription Costs: Most Mounjaro prescriptions for weight management are currently issued privately. Indicative monthly costs through Boots have been reported at approximately £176 to £334 per month; other private clinics and online prescribing services may charge differently. Prices shown are indicative and may have changed. Always check directly with the provider for current pricing, as costs vary depending on the dose, plan, and any ongoing promotions. These costs are borne entirely by the patient.

Cost-Benefit Considerations: Patients should weigh the financial commitment against expected health benefits. The SURMOUNT-1 trial demonstrated average weight loss of approximately 15 to 20% of body weight over 72 weeks when tirzepatide was combined with lifestyle interventions, though individual results vary.^[4] The SURMOUNT-2 trial showed that average weight loss is typically lower in people with type 2 diabetes than in those without.^[4] Evidence from withdrawal studies (including SURMOUNT-4) indicates that weight regain occurs when treatment is stopped, meaning long-term use is generally required to maintain weight loss. Affordability is therefore a crucial consideration before starting treatment.

How to Access Mounjaro Through Boots

Patients access Mounjaro through Boots by completing an online health questionnaire via Boots Online Doctor or visiting a participating pharmacy, with eligibility requiring a BMI of 30 kg/m² or above, or 27 kg/m² or above with a weight-related health condition.

Accessing Mounjaro through Boots Pharmacy involves a structured clinical pathway designed to ensure patient safety and treatment appropriateness.

Eligibility Criteria: To qualify for Mounjaro through Boots, patients typically must meet criteria aligned with the medication's licence: a body mass index (BMI) of 30 kg/m² or above, or a BMI of 27 kg/m² or above with at least one weight-related health condition (such as type 2 diabetes, hypertension, or dyslipidaemia). Patients must be aged 18 or over.

Key Safety Information: The following points are drawn from the UK SmPC and are important for all patients considering this treatment.

Mounjaro is contraindicated in patients with hypersensitivity to tirzepatide or any of the excipients. It should not be used during pregnancy and should be avoided during breastfeeding.

Patients should be aware of the following warnings consistent with the UK SmPC: risk of pancreatitis (if you develop severe and persistent abdominal pain, which may radiate to the back, stop treatment and seek urgent medical attention); gallbladder disease (report symptoms such as upper abdominal pain, fever, or jaundice promptly); risk of dehydration due to nausea, vomiting, or diarrhoea (maintain adequate fluid intake and seek advice if unable to do so); and a general caution regarding pre-existing thyroid disease (discuss with your prescriber; note that the MEN2/MTC contraindication listed in some US prescribing information does not appear in the UK SmPC).

If you experience signs of a severe allergic reaction (such as difficulty breathing, swelling of the face or throat, or a rapid heartbeat), seek emergency medical attention immediately.

Patients taking insulin or sulfonylureas alongside tirzepatide have an increased risk of hypoglycaemia. Your prescriber may need to review and adjust the doses of those medicines before or after starting tirzepatide.

Oral contraceptive efficacy may be reduced during tirzepatide treatment due to delayed gastric emptying. The UK SmPC advises switching to a non-oral contraceptive method, or adding a barrier method, for four weeks after starting tirzepatide and for four weeks after each dose increase.

The Application Process: Patients begin by completing an online health questionnaire through the Boots Online Doctor service or by visiting a participating Boots pharmacy. A qualified prescriber reviews the application. If approved, the prescriber issues a private prescription and provides guidance on administration, expected side effects, and lifestyle modifications.

Ongoing Monitoring: Treatment initiation includes education on subcutaneous injection technique, as Mounjaro is administered weekly via pre-filled pen. Boots provides follow-up consultations at regular intervals to monitor progress, assess tolerability, and adjust dosing.

Storage: Store Mounjaro in a refrigerator (2 to 8 degrees Celsius); do not freeze; keep in the original carton to protect from light. According to the UK SmPC, the pen may be kept at room temperature (up to 30 degrees Celsius) for up to 21 days. Discard if not used within this period. Confirm current storage guidance with your pharmacist or the patient information leaflet supplied with your medicine.

Report any suspected side effects to the MHRA Yellow Card Scheme at yellowcard.^[5]mhra.gov.uk or via the Yellow Card app.

Alternative Weight Management Options and Costs

Alternatives to Mounjaro include NHS Tier 2 and 3 weight management services at no direct cost, orlistat on prescription or over the counter, Wegovy (semaglutide) or Saxenda (liraglutide) privately, and bariatric surgery for those meeting NICE eligibility criteria.

For patients unable to afford or access Mounjaro, several alternative weight management options exist within both NHS and private sectors, each with distinct cost implications and evidence bases.

NHS Tier 2 and 3 Services: The NHS offers structured weight management programmes at no direct cost to patients. Tier 2 services provide community-based lifestyle interventions, including dietary advice, physical activity support, and behavioural change programmes, typically delivered over 12 to 16 weeks. Tier 3 services offer more intensive, specialist multidisciplinary support for individuals with complex obesity, often including psychological input and management of comorbidities. Tier 4 corresponds to bariatric and metabolic surgery. Referral criteria and waiting times vary by region and local ICB; contact your GP for information on what is available locally. NHS information on weight management services is available at nhs.uk.

Alternative Medications: Other licensed weight management medicines available in the UK include orlistat (available over the counter or on NHS prescription), which works by reducing fat absorption. Wegovy (semaglutide), a GLP-1 receptor agonist, is NICE-recommended for weight management and may be available through NHS specialist services; private prescription costs vary by provider and dose. Saxenda (liraglutide), another GLP-1 receptor agonist requiring daily rather than weekly injection, is also available privately. Indicative private costs for these medicines have been quoted in various sources but change frequently; always check directly with the provider for current pricing. Availability of semaglutide and liraglutide has also been affected by supply constraints, as noted in DHSC and NHS England supply alerts.

Bariatric Surgery: For individuals with a BMI of 40 kg/m² or above (or 35 kg/m² or above with comorbidities), bariatric surgery represents a highly effective intervention. NICE guidance (CG189) and NG28 (type 2 diabetes in adults) set out eligibility criteria, including lower BMI thresholds for certain ethnic groups and for people with type 2 diabetes; refer to the current NICE guidance for precise thresholds. NHS-funded surgery is available following assessment by specialist services, though waiting times can be substantial. Private bariatric surgery costs vary widely; contact accredited providers directly for current pricing.

Commercial Weight Loss Programmes: Evidence-based commercial programmes such as WW (Weight Watchers) or Slimming World provide structured support, accountability, and peer networks. Costs and NHS referral availability vary; check with your GP or local authority for current arrangements.

Frequently Asked Questions